New Delhi, Aug 31 (IANS) For those suffering from uncontrolled hypertension, here comes good news. New research on Saturday showed that a single pill with low doses of three anti-hypertensive drugs, once a day, significantly lowered blood pressure than other standard care methods.
It is estimated that over a billion adults live with hypertension worldwide, with two-thirds living in low- and middle-income countries.
The treatment based on novel combination of low doses of three anti-hypertensive drugs in a single pill – known as ‘GMRx2’ – was found to be superior to a high-quality standard care treatment plan at lowering blood pressure in patients, according to the study published in the Journal of the American Medical Association (JAMA).
The ‘GMRx2’ treatment plan involved a once daily pill containing telmisartan, amlodipine and indapamide at a quarter, half or standard doses.
The standard care treatment plan was recommended by the Nigerian Ministry of Health began with monotherapy, followed by dual and triple combination therapy, and was typical of hypertension guidelines for many countries.
Results of the trial was led by The George Institute for Global Health and presented at the ‘European Society of Cardiology Congress 2024’.
After six-month treatment, home systolic blood pressure was 31 mm Hg lower in the ‘GMRx2’ group compared to 26 mm Hg lower with standard care. The 5.8 mm Hg difference was highly clinically and statistically significant.
Existing evidence shows that with every 5 mm Hg reduction in systolic blood pressure there is a 10 per cent reduction in major cardiovascular events such as stroke, heart attack and heart failure, the study noted.
After just one month, 81 per cent of participants in the ‘GMRx2’ group achieved clinic-measured blood pressure control versus 55 per cent with standard care.
“The triple pill still produced clinically meaningful reductions in blood pressure compared to standard care, even when standard care closely followed current guidelines and involved more clinic visits,” said Professor Dike Ojji, head of the cardiovascular research unit at the University of Abuja, Nigeria.
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
